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INTRODUCTION
Patients with autonomic failure experience disabling postural dizziness, syncope, falls, constipation and incontinence. [1] There is a need to identify symptomatic dysautonomia in dementia in order to ensure appropriate management and reduce risk of falls, which is particularly important as falls are a significant cause of increased morbidity, institutionalisation and mortality in these individuals. [2] There are no previous prospective studies of autonomic function comparing the most common dementia subtypes in the elderly; Alzheimer's disease (AD) Parkinson's disease [4] emphasises early involvement of the brainstem, including the dorsal vagal nucleus, and autonomic failure is a feature of Parkinson's disease. [5] The only previous studies using standard bedside clinical autonomic tests have mainly included patients with AD only, [6] [7] [8] [9] [10] although two have included patients with multi-infarct dementia or Binswanger's encephalopathy, [11, 12] and there is one retrospective report of clinical autonomic dysfunction in DLB patients. [13] Studies using bedside tests do require a level of cooperation by the subject which may not be possible in dementia. These data can be enhanced by measurements of heart rate variability, [14] which requires less cooperation from the subject than other autonomic function tests and is suitable for use in patients with dementia. [15] We examined autonomic function using a combination of standardized bedside clinical testing and heart rate variability techniques, in an unselected series of patients with a range of dementia subtypes, diagnosed according to well validated diagnostic Participants were excluded if they were in atrial fibrillation or had other arrhythmias.
Controls were excluded if they had any evidence of dementia or Parkinson's disease.
Clinical Assessment
All patients received a full medical assessment, including physical examination and 12 lead electrocardiogram. Significant medical causes of dementia were excluded during diagnostic investigations. Duration of dementia, drug history and history of hypertension or diabetes mellitus were recorded. Cognitive function was assessed using the cognitive subsection of the Cambridge Examination for Mental disorders in the elderly (CAMCOG) [21] . All assessments took place in the morning; participants were asked to take their usual medications including dopaminergic agents, and to refrain from drinking caffeinated drinks or smoking on the morning on the assessment.
Extra-pyramidal signs were evaluated using the motor subsection of the Unified
Parkinson's disease rating scale (UPDRS), [22] after taking the usual dose of levodopa, if applicable.
Clinical Autonomic Function Tests
Clinical autonomic function tests were carried out according to Ewing's battery. [23] The electrocardiogram (ECG) was recorded during supine rest using standard limb leads I or II and locally developed software, sampling at 1 kHz. Blood pressure was monitored using a digital photoplethysmograph (Portapres, TNO, Amsterdam) which enables non invasive beat to beat blood pressure measurement. Blood pressure data were synchronised to ECG and inspected off line for artefacts, ectopic beats and non systolic waveforms which were removed using a semi-automated technique.
Participants rested in the supine position for 10 minutes before starting the tests and also rested for 2 minutes between each test. Heart rate tests were excluded if invalidated by excessive ectopic activity or other arrhythmia. Blood pressure tests were excluded if the trace was obscured by movement artefact.
Parasympathetic tests

Deep breathing
Respiratory sinus arrhythmia was assessed by the performance of 6 deep breaths at a frequency of 0·1 Hz. Participants were given adequate rehearsal to achieve the required frequency and counted through the 6 breaths. The response was taken as the mean of the differences between the maximum and minimum instantaneous heart rate for each cycle. A minimum of 3 breaths was required for inclusion.
Orthostasis
Orthostatic blood pressure and heart rate changes were assessed during a 3 minute active stand. Heart rate response to standing was assessed as the ratio of maximum R-R interval at or around the 30 th beat to the minimum R-R interval at or around the 15 th beat.
Valsalva ratio
The Valsalva manoeuvre was performed for 15 seconds, requiring forced expiration against an open glottis at a pressure of 40 mmHg. The pressure achieved was monitored via the PC and visual feedback was available to the participant to enable them to maintain a constant pressure. The manoeuvre was performed three times in order to maximise participant compliance and ensure reproducibility. The best response was used for analysis and a minimum of 12 seconds was required for inclusion.
Valsalva ratio was taken as the maximum R-R interval in the 15 seconds following expiration divided by the minimum R-R interval during the manoeuvre.
Sympathetic tests
Orthostasis
Orthostatic blood pressure change was calculated as the difference between the nadir blood pressure immediately after standing and the mean blood pressure for the 20 beats immediately prior to standing.
Valsalva manoeuvre
Blood pressure response was taken as the difference between the peak systolic blood pressure achieved during phase IV and the mean systolic blood pressure for the 20 beats immediately prior to the manoeuvre.
Isometric exercise
This was performed by rising from the supine to a sitting position, and remaining in that position for 3 minutes, without external help. The blood pressure response was taken as the difference between the mean diastolic blood pressure for the 20 beats immediately prior to sitting and the 20 beats immediately prior to the end of the sitting exercise. A minimum of 90 seconds was required for inclusion.
Measurement of Heart Rate Variability
ECG was recorded as described above. Five minutes of RR interval data were digitised and stored on computer for subsequent off-line analysis (Lab View and data acquisition card 1200, National Instruments, Newbury). Non sinus beats were removed automatically, then manually if necessary, using an R wave detection software package: the program interpolated an R wave for missed or ectopic beats. [24] The record was excluded if excessive ectopic activity or any period of supraventricular arrhythmia were present. Power spectral analysis (Fast Fourier transformation) of the edited recording was performed to obtain spectral bands in the very low (<0·04Hz), low (0·04-0·15Hz) and high (0·15-0·40Hz) frequency bands and also total spectral power (<0·40Hz) according to international guidelines. [14] Sympathovagal balance was examined by low frequency: high frequency ratio.
Sustained orthostatic hypotension was defined as a fall in systolic blood pressure of greater than 20 mm Hg or diastolic blood pressure of greater than 10 mm Hg which did not return to baseline within 30 seconds from the start of the active stand. Time of return to baseline was defined as the start of the first series of 3 consecutive beats in the blood pressure which were within one standard deviation of the baseline blood pressure.
Ewing classification of autonomic failure
Results for each bedside autonomic test were classified as normal or abnormal. A test was deemed to be abnormal if the result was below the 5 th percentile for that test in the control group, and borderline if below the 10 th percentile. Ewing's classification of autonomic function [23] was determined as shown below for each patient who had complied with sufficient tests for the classification scheme to be applied.
Normal: all tests normal or 1 borderline
Early: one of the 3 heart rate tests abnormal or 2 borderline Definite: two or more of the heart rate tests abnormal Severe: two or more of the heart rate tests abnormal plus one or both of the BP tests abnormal or both borderline Atypical: any other combination
Statistics
Fisher's Exact test was used to detect the presence of differences across groups in the categorical baseline characteristics (gender, history of hypertension, diabetes mellitus, levodopa or cardiovascular drug usage). ANOVA was used to compare differences across groups in normally distributed data (age, CAMCOG, levodopa dose). Duration of dementia, number of cardiovascular medications and UPDRS score data were not normally distributed, therefore, Kruskal-Wallis tests were used to test for differences across groups and Mann-Whitney U test to compare differences between individual groups.
Univariate ANOVA analyses were used to establish the presence of significant differences in autonomic function tests across diagnostic groups. Heart rate variability data were transformed using the natural logarithm to produce a normal distribution.
Cox regression was used to compare time of return to baseline systolic blood pressure as this was a censored event, and Fisher's Exact tests were used to compare categorical outcomes (orthostatic hypotension, Ewing classification). On the basis of our prior hypotheses, if significant differences across groups were present predefined comparisons between groups were made (univariate ANOVA or Pearson's Chi squared as appropriate). These compared each disease group with the control group, the DLB and PDD groups with the AD group and the DLB group with the PDD group.
Post hoc multivariate linear regression analyses were performed to examine the potential confounding effects of age, gender, duration of dementia, hypertension, diabetes and cardiovascular medications.
All statistical tests were performed using SPSS version 11.0 statistics package.
Significance was taken as p <0·05.
RESULTS
Participant characteristics
One hundred and ninety eight participants met the initial inclusion criteria (42 VAD, 40 PDD and 30 DLB). Table 1 shows the baseline characteristics of the participants. There were no differences in gender between groups (all p>0·05). VAD patients were older than controls (mean difference 3·9 +/-1·6 years, p=0·002), and PDD patients were younger than controls (mean difference 3·9 +/-1·4 years, p=0·007). Patients with VAD had a shorter duration of dementia than those in the AD or PDD groups (p=0·002, 0·008 respectively). All dementia groups had lower CAMCOG scores than controls (all p<0·001) but the dementia groups were not different from one another.
Hypertension was more common in VAD than in all other groups and less common in DLB than in controls (VAD vs. other groups all p<0·01, control vs. DLB p=0·017), but there were no significant differences between groups in other factors potentially affecting autonomic function. All patient groups had higher UPDRS scores than controls (all p< 0·001). 
Number (%) receiving levodopa therapy χ 2 : p<0.001 Mean daily dose (mg) Patients with VAD had impaired heart rate responses to standing and Valsalva manoeuvre in comparison with controls (p=0·017, p=0·008 respectively), but only the difference in Valsalva ratio remained significant in multivariate analyses (p=0·04).
There were no significant differences in parasympathetic tests between AD patients and the control group.
PDD patients were more impaired in comparison with AD patients on all parasympathetic tests (all p<0·05). DLB patients had more impaired heart rate responses to deep breathing in comparison with AD patients (p=0·003). In multivariate analyses, both DLB and PDD patient groups were more impaired in comparison with AD patients on all parasympathetic tests (all p<0·05), except DLB vs.
AD on response to standing (p=0.071). PDD patients had a more impaired Valsalva ratio than DLB patients (p=0·024) and this difference remained in multivariate analyses (p=0·014). The results of other predefined contrasts are given in the right hand column.
All significant results are shown in boldface. 
Diagnosis
Clinical autonomic testing: Sympathetic tests
All patient groups had a greater fall in blood pressure upon standing than controls, remaining significant in multivariate analyses (all p<0·05) ( The results of other predefined contrasts are given in the right hand column. All significant results are shown in boldface.
Heart Rate Variability
ANOVA analyses across all groups showed significant differences in total spectral power, low frequency band and high frequency band (p=0·040, 0·041, 0·003 respectively, table 4). There were no differences across groups in mean R-R interval, very low frequency band and low frequency: high frequency ratio (p= 0·372, 0·113, 0·428, respectively).
Total spectral power, low frequency power and high frequency power were reduced in PDD patients in comparison with healthy controls; differences remaining in multivariate analyses (all p< 0·05). Total spectral power, low frequency band and high frequency band were also reduced in comparison with the AD patient group. DLB patients were not significantly different from controls in univariate ANOVA but the low frequency band was significantly reduced in multivariate analyses (p=0·021). Table 4 P values in the left hand column give the result of the univariate ANOVA across all groups.
Columns 3-6: show the mean (95% confidence intervals for the mean) for each heart rate variability test by diagnosis, with p values for that patient group in comparison with the control group in univariate ANOVA, and in multivariate analyses in brackets.
The results of other predefined contrasts are given in the right hand column.
All significant results are shown in boldface. , table 5 ). Consistent with this, time for blood pressure to return to baseline after standing was significantly longer for AD, DLB and PDD in comparison with controls, remaining significant in multivariate analyses. Table 6 shows the number of cases with each Ewing classification of autonomic neuropathy by diagnostic group, and the total number of cases (%)with definite, atypical or severe autonomic neuropathy. In comparison with controls, all patient groups were more likely to have an autonomic neuropathy and severe, definite and atypical autonomic neuropathy than controls (all p<0·05). PDD patients were more likely to have an autonomic neuropathy than other patient groups (AD: p=0·001, VAD: p=0·024, DLB: p=0·024). The results of other predefined contrasts are given in the right hand column.
Diagnosis (n) CONTROL
Ewing classification
All significant results are shown in boldface.
TABLE 6: CLINICAL AUTONOMIC FUNCTION TESTS (EWING CLASSIFICATION)
Legend to Table 6 It was not possible to classify all participants, as some were unable to complete sufficient autonomic tests to enable the Ewing classification to be calculated. Participants with dementia were less likely to have sufficient results to determine Ewing classification than were controls, but there were no differences between patient groups.
Diagnosis (n)
CONTROL ( PDD and DLB cases both showed evidence of parasympathetic dysfunction on clinical testing, and apart from the Valsalva ratio the degree of impairment was similar. However, on sympathetic testing, PDD patients were more impaired than DLB patients, although there was some evidence of sympathetic dysfunction in DLB in multivariate analyses. Both AD and VAD patients had a higher prevalence of sustained orthostatic hypotension and autonomic neuropathy than controls, but in other group comparisons did not differ from controls.
There has been considerable debate about the diagnostic concepts of PDD and DLB.
It has been suggested that in PD Lewy body pathology begins in the brainstem and progresses to the neocortex. [25] However, there may be a different pattern of evolution in DLB, with some studies suggesting that cerebrocortical pathology predominates in DLB, [26, 27] although prominent Lewy body pathology is still evident in the brain stem, including the dorsal vagal nucleus.
[28] In our study the profile of parasympathetic abnormalities in PDD and DLB suggest that there is significant central autonomic involvement of the dorsal vagal nucleus in both conditions. Inevitably, the patients with PDD were taking a higher dose of levodopa, reflecting the duration of their disease. In comparisons between PDD and DLB, use of levodopa and dose are not constantly correlated, but the correlation is strong.
Adjustment for levodopa use or dose in the multivariate analyses comparing PDD and DLB would therefore result in the significant differences being lost. However, this does not necessarily mean that differences between PDD and DLB were solely due to the pharmacological effect of levodopa. It is more likely that they are measuring a similar variable, namely the extent of brainstem disease, as opposed to cortical disease.
The origin of sympathetic dysfunction in Lewy body diseases has been thought to be mainly due to peripheral sympathetic denervation. The study included an appropriately aged control group, which is of importance because autonomic function declines with age. [35] Although the controls were slightly older than the PDD group (mean difference 3.9 +/-1.4 years), this strengthens the finding that dysautonomia is most impaired in PDD, as it is likely that even greater differences would have been found if the PDD cases were compared with younger controls. Unfortunately, the VAD group were slightly older than the control group (mean difference 3.9 +/-1.6 years), and this leads to some uncertainty with respect to the findings in this group. The abnormalities in the heart rate responses to standing and Valsalva manoeuvre may not have been present if comparisons had been made with an older control group. In addition some of the responses to the Ewing tests might not have been classified as abnormal or borderline if they were compared to a more closely age matched control group, with the result that the prevalence of autonomic neuropathy could have been overestimated. Nevertheless, the number of abnormal findings in our VAD group was few, and therefore we are able to conclude that there is not substantial dysautonomia in VAD, and that comparison with an older control group would be likely to improve the strength of this finding.
We conclude that autonomic dysfunction can occur in all common dementias in older people, but is a particularly common feature of DLB and PDD. The high prevalence of autonomic neuropathy and sustained orthostatic hypotension in dementia has potentially important implications for patient management.
